MOORESTOWN, N.J., Sept. 11, 2017 -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today announced that an unprecedented 100% of its eligible clinicians within subsidiary CareKinesis, have achieved Board Certified Geriatric Pharmacist (BCGP) recognition. The certification distinguishes pharmacists for their in-depth knowledge of geriatric drug therapy and as preferred providers of care for seniors.
|
|||
Today’s older adults have unique medication management needs as they manage multiple diseases and medications at the same time. However, traditional training of health professionals focuses on basic physiology, diseases, and use of medication to treat a particular disease, according to the Commission for Certification in Geriatric Pharmacy (CCGP), the national program for accredited certification of BCGPs. As a result, most prescribers and pharmacists tend to focus on the treatment of one disease or the use of one drug at a time. BCGPs are trained to look at the whole patient, evaluate all the diseases he/she is being treated for and evaluate the current medication regiment for its overall safety and effectiveness, potentially avoiding unnecessary hospital admissions and adverse drug events (ADEs).
“TRHC’s geriatric-certified pharmacists know that the focus must be on the total patient, looking at all relevant intrinsic and extrinsic factors to evaluate appropriateness of drug therapy,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Medication safety remains our highest priority, for our people and through the technologies we provide to the market. This is an unprecedented achievement for our subsidiary company, CareKinesis, which achieved the 100% certification.”
Pharmacists who meet CCGP’s criteria and pass the examination are entitled to use the designation “Board Certified Geriatric Pharmacist” and place the initials BCGP after their name.
“When I need it, I want a Board Certified Geriatric Pharmacist on my own healthcare team,” said Robert L. Alesiani, PharmD, BCGP and Chief Pharmacotherapy Officer for CareKinesis. “I believe BCGPs are more likely to help decrease medication-related risk, reduce adverse drug events and enhance compliance, adherence and quality of life.”
“Thanks to Dr. Alesiani’s leadership and example, 100% of our eligible staff have taken and passed this rigorous exam,” said Dr. Knowlton. “We congratulate our pharmacists and thank them for the tremendous service they provide in assuring the best possible personalized medication therapy care.”
About Tabula Rasa HealthCare, Inc.
Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Since 2011, TRHC, through its wholly-owned subsidiary, CareKinesis, has focused on optimizing outcomes for PACE and other healthcare organizations using its unique Medication Risk Mitigation software and Medication Decision Support and Adherence tools that personalize each participants medication regimen. For more information, please visit: www.TRHC.com.
Contact:
TRHC
Dianne Semingson
[email protected]
T: 215-870-0829


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Italy Fines Apple €98.6 Million Over App Store Dominance 



